IP Library Granted Patent US 11,117,915
Granted Patent B2
US 11,117,915 · App. 16/678,931 · Granted Sep 14, 2021

Antibacterial aminoglycoside analogs

Inventors: James Bradley Aggen (Burlingame, CA); Adam Aaron Goldblum (Berkeley, CA); Martin Sheringham Linsell (San Mateo, CA); Paola Dozzo (San Francisco, CA); Heinz Ernst Moser (San Mateo, CA); Darin James Hildebrandt (Cupertino, CA); Micah James Gliedt (Sunnyvale, CA)
Assignee: CIPLA USA, INC.
C07H15/224A61K31/7036C07H15/222C07H15/236Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,117,915
App. No.
16/678,931
Granted
Sep 14, 2021
Kind
B2
Abstract

Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q 1 , Q 2 , Q 3 , R 8 and R 9 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Claims (48)

1. A compound having the following structure (I):

or a stereoisomer, or a pharmaceutically acceptable salt thereof,

wherein:

Q 1 is hydrogen;

Q 2 is hydrogen, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, —C(═NH)NR 4 R 5 , —(CR 10 R 11 ) p R 12 ,

Q 3 is hydrogen, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, —C(═NH)NR 4 R 5 , —(CR 10 R 11 ) p R 12 ,

each R 1 , R 2 , R 3 , R 4 , R 5 , R 8 and R 10 is, independently, hydrogen or C 1 -C 6 alkyl, or R 1 and R 2 together with the atoms to which they are attached can form a heterocyclic ring having from 4 to 6 ring atoms, or R 2 and R 3 together with the atoms to which they are attached can form a heterocyclic ring having from 4 to 6 ring atoms, or R 1 and R 3 together with the atoms to which they are attached can form a carbocyclic ring having from 4 to 6 ring atoms, or R 4 and R 5 together with the atom to which they are attached can form a heterocyclic ring having from 4 to 6 ring atoms;

each R 6 and R 7 is, independently, hydrogen, hydroxyl, amino or C 1 -C 6 alkyl, or R 6 and R 7 together with the atoms to which they are attached can form a heterocyclic ring having from 4 to 6 ring atoms;

each R 9 is, independently, hydrogen or methyl;

each R 11 is, independently, hydrogen, hydroxyl, amino or C 1 -C 6 alkyl;

each R 12 is, independently, hydroxyl or amino;

each n is, independently, an integer from 0 to 4;

each m is, independently, an integer from 0 to 4; and

each p is, independently, an integer from 1 to 5, and

wherein at least one of Q 2 and Q 3 is —C(═NH)NR 4 R 5 .

2. A compound of claim 1 , wherein R 8 is hydrogen.

3. A compound of claim 1 , wherein each R 9 is methyl.

4. A compound of claim 1 , wherein Q 3 is hydrogen.

5. A compound of claim 1 , wherein Q 2 is —(CR 10 R 11 ) p R 12 .

6. A compound of claim 5 wherein each R 10 is hydrogen.

7. A compound of claim 6 wherein each R 11 is hydrogen.

8. A compound of claim 1 , wherein Q 2 is optionally substituted cycloalkylalkyl.

9. A compound of claim 8 wherein Q 2 is unsubstituted.

10. A compound of claim 8 wherein Q 2 is substituted with hydroxyl or amino.

11. A compound of claim 1 , wherein Q 2 is optionally substituted heterocyclylalkyl.

12. A compound of claim 11 wherein Q 2 is unsubstituted.

13. A compound of claim 11 wherein Q 2 is substituted with hydroxyl or amino.

14. A compound of claim 1 , wherein Q 3 is —(CR 10 R 11 ) p R 12 .

15. A compound of claim 14 wherein each R 10 is hydrogen.

16. A compound of claim 15 wherein each R 11 is hydrogen.

17. A compound of claim 1 , wherein Q 3 is optionally substituted cycloalkylalkyl.

18. A compound of claim 17 wherein Q 3 is unsubstituted.

19. A compound of claim 17 wherein Q 3 is substituted with hydroxyl or amino.

20. A compound of claim 1 , wherein Q 3 is optionally substituted heterocyclylalkyl.

21. A compound of claim 20 wherein Q 3 is unsubstituted.

22. A compound of claim 20 wherein Q 3 is substituted with hydroxyl or amino.

23. A compound of claim 1 , wherein Q 3 is optionally substituted heterocyclyl.

24. A compound of claim 23 wherein Q 3 is unsubstituted.

25. A compound of claim 23 wherein Q 3 is substituted with hydroxyl or amino.

26. A compound of claim 1 , wherein Q 2 is —C(═NH)NH 2 .

27. A compound of claim 1 , wherein Q 3 is —C(═NH)NH 2 .

28. A compound of claim 1 , wherein the compound is:

6′,2′-bis-Guanidinium-sisomicin;

6′-(2-Hydroxy-ethyl)-2′-guanidinium-sisomicin;

6′-(Methyl-trans-3-amino-cyclobutyl)-2′-guanidinium-sisomicin; or

6′-Methyl-2′-guanidinium-sisomicin.

29. A pharmaceutical composition comprising a compound of claim 1 , or a stereoisomer, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

30. A method of treating a bacterial infection in a mammal in need thereof, comprising administering to the mammal an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2020
From: ACHAOGEN, INC.
To: CIPLA USA, INC.
Reel/Frame 052159/0853 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2020
From: AGGEN, JAMES BRADLEY; GOLDBLUM, ADAM AARON; LINSELL, MARTIN SHERINGHAM; DOZZO, PAOLA; MOSER, HEINZ ERNST; HILDEBRANDT, DARIN JAMES; GLIEDT, MICAH JAMES
To: ACHAOGEN, INC.
Reel/Frame 052088/0151 →